SCHEMBL20181728

SCHEMBL20181728

CN1CCN(c2ccc(C(=O)Nc3cc(-c4ccoc4)ccc3NC(=O)OC(C)(C)C)nc2)CC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 10/20 0.71
HDAC2 Q92769 7/20 0.71
KCNH2 Q12809 4/20 0.53
CYP1A2 P05177 2/20 0.53
CYP2C18 P33260 1/20 0.53
CYP2C19 P33261 1/20 0.53
SLC2A1 P11166 1/20 0.43
CDK4 P11802 1/20 0.42
CCND1 P24385 1/20 0.42
KMT2A Q03164 3/20 0.42
WDR5 P61964 1/20 0.42
MEN1 O00255 2/20 0.40
USP2 O75604 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
HIF1A Q16665 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
MAP3K7 O43318 1/20 0.40
FGFR1 P11362 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20163050 0.92 HDAC3 (0.60) HDAC3HDAC2KCNH2CYP1A2CYP2C18
SCHEMBL23960951 0.88 HDAC3 (0.59) HDAC3HDAC2KCNH2CYP1A2CYP2C18
SCHEMBL20163045 0.88 HDAC3 (0.69) HDAC3HDAC2KCNH2CYP1A2CYP2C18
SCHEMBL20181681 0.87 KCNH2 (0.70) HDAC3HDAC2KCNH2CYP1A2CYP2C18
SCHEMBL20181720 0.86 HDAC3 (0.72) HDAC3HDAC2KCNH2CYP1A2CYP2C18
SCHEMBL20163073 0.84 HDAC2 (0.72) HDAC3HDAC2KCNH2SMN1; SMN2
SCHEMBL20181696 0.84 HDAC3 (0.72) HDAC3HDAC2KCNH2CYP1A2CYP2C18
SCHEMBL20181533 0.83 HDAC2 (1.00) HDAC3HDAC2KCNH2CYP1A2CYP2C18
SCHEMBL23960982 0.83 HDAC3 (0.48) HDAC3HDAC2KCNH2KMT2AMEN1
SCHEMBL23960952 0.82 HDAC3 (0.53) HDAC3HDAC2KCNH2CYP1A2CYP2C18

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11542242-B2 Substituted piperazines as selective HDAC1,2 inhibitors REGENACY PHARMACEUTICALS, LLC (US) 2023-01-03 US disclosed
US-20200377465-A1 SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS REGENACY PHARMACEUTICALS, LLC 2020-12-03 US disclosed
US-10774056-B2 Substituted piperazines as selective HDAC1,2 inhibitors REGENACY PHARMACEUTICALS, INC. (US) 2020-09-15 US disclosed
US-20190330169-A1 SELECTIVE HDAC1,2 INHIBITORS REGENACY PHARMACEUTICALS, LLC 2019-10-31 US disclosed
US-10385031-B2 Substituted piperazines as selective HDAC1,2 inhibitors REGENACY PHARMACEUTICALS, LLC (US) 2019-08-20 US disclosed
US-20180141923-A1 SELECTIVE HDAC1,2 INHIBITORS REGENACY PHARMACEUTICALS, LLC 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10385031-B2 Substituted piperazines as selective HDAC1,2 inhibitors HDAC1, HDAC2, HDAC11 HDAC3 7/4885HDAC2 2/4885KCNH2 3509/4885
US-11542242-B2 Substituted piperazines as selective HDAC1,2 inhibitors HDAC1, HDAC2, HDAC11 HDAC3 8/4885HDAC2 2/4885KCNH2 3232/4885
US-20180141923-A1 SELECTIVE HDAC1,2 INHIBITORS HDAC1, HDAC2, HDAC11 HDAC3 6/4885HDAC2 2/4885KCNH2 4371/4885
US-10774056-B2 Substituted piperazines as selective HDAC1,2 inhibitors HDAC1, HDAC2, HDAC11 HDAC3 7/4885HDAC2 2/4885KCNH2 3225/4885
US-20200377465-A1 SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS HDAC1, HDAC2, HDAC11 HDAC3 7/4885HDAC2 2/4885KCNH2 3551/4885
US-20190330169-A1 SELECTIVE HDAC1,2 INHIBITORS HDAC1, HDAC2, HDAC11 HDAC3 6/4885HDAC2 2/4885KCNH2 4371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.